Want to see HK:2257 full AI Analyst Report?
Top Page
Sirnaomics Ltd.
(2257)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$3.50
▼(-6.67% Downside)
Action:Reiterated
Date:08/22/26
The score is primarily held down by weak financial performance: zero revenue in 2025, continued losses and cash burn, and a high-risk balance sheet with negative shareholder equity. Technicals also detract, with the stock trading below all major moving averages and negative momentum indicators. Valuation provides limited support due to negative earnings and no stated dividend yield.
Positive Factors
Specialized RNAi Therapeutics Platform
A focused RNAi platform gives Sirnaomics a specialized technology base in a potentially important therapeutic modality, supporting differentiated research capabilities and the possibility of building value through successful clinical development.
Negative Factors
No Current Revenue Scale
Zero revenue highlights the absence of a reliable commercial base and leaves the company dependent on clinical progress, partnerships, or external financing. Limited scale also makes fixed research and development costs harder to absorb.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized RNAi Therapeutics Platform
A focused RNAi platform gives Sirnaomics a specialized technology base in a potentially important therapeutic modality, supporting differentiated research capabilities and the possibility of building value through successful clinical development.
Read all positive factors
Sirnaomics Ltd. (2257) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$423.95M
Dividend YieldN/A
Average Volume (3M)52.83K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth-100.00%
EPS Growth30.94%
CountryHK
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding112,157,135
10 Day Avg. Volume49,555
30 Day Avg. Volume52,825
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-9.39
Price to Sales (P/S)0.00
P/FCF Ratio-10.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$162.00M
Sirnaomics Ltd. Business Overview & Revenue Model
Company Description
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant ...
How the Company Makes Money
null...
Sirnaomics Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 1.78M | 397.00K | 705.00K | 0.00 |
| Gross Profit | -1.55M | -1.84M | 1.20M | 397.00K | 705.00K | -12.67M |
| EBITDA | -12.39M | -13.53M | -31.12M | -72.36M | -89.02M | -1.66B |
| Net Income | -10.63M | -14.42M | -51.38M | -78.69M | -88.30M | -1.66B |
Balance Sheet | ||||||
| Total Assets | 13.42M | 20.60M | 28.33M | 75.79M | 163.93M | 240.65M |
| Cash, Cash Equivalents and Short-Term Investments | 7.19M | 13.52M | 11.77M | 43.93M | 105.23M | 211.99M |
| Total Debt | 25.26M | 9.31M | 8.06M | 8.85M | 10.76M | 7.04M |
| Total Liabilities | 34.50M | 45.09M | 44.33M | 51.33M | 52.37M | 30.36M |
| Stockholders Equity | -6.06M | -9.91M | -1.68M | 40.20M | 122.01M | 211.62M |
Cash Flow | ||||||
| Free Cash Flow | -9.11M | -9.25M | -19.84M | -72.03M | -107.54M | -62.85M |
| Operating Cash Flow | -9.10M | -9.20M | -19.73M | -70.29M | -88.71M | -56.97M |
| Investing Cash Flow | -1.41M | 23.00K | 2.14M | -5.35M | -32.61M | -6.04M |
| Financing Cash Flow | 10.75M | 10.95M | 5.82M | -5.61M | 15.89M | 170.96M |
Sirnaomics Ltd. Technical Analysis
Negative
3.75
Price Trends
4.14
Negative
4.93
Negative
6.28
Negative
Market Momentum
-0.09
Negative
42.57
Neutral
30.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2257, the sentiment is Negative. The current price of 3.75 is below the 20-day moving average (MA) of 3.95, below the 50-day MA of 4.14, and below the 200-day MA of 6.28, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 42.57 is Neutral, neither overbought nor oversold. The STOCH value of 30.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2257.
Sirnaomics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$4.82B | 7.97 | 47.76% | ― | 286.20% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$8.23B | -41.48 | -10.27% | ― | -31.77% | -177.01% | |
45 Neutral | HK$12.67B | -7.18 | -153.78% | ― | 70.26% | -12.79% | |
45 Neutral | HK$436.45M | -1.52 | -32.08% | ― | 215.14% | 40.49% | |
44 Neutral | HK$7.98B | -66.50 | -9.49% | ― | 68.12% | 81.84% | |
42 Neutral | HK$423.95M | -4.51 | 133.13% | ― | -100.00% | 30.94% |
* Healthcare Sector Average
HK:2257
Sirnaomics Ltd.
3.86
-14.93
-79.47%
HK:9966
Alphamab Oncology
8.33
-2.17
-20.67%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
6.06
-4.29
-41.44%
HK:2171
CARsgen Therapeutics Holdings Ltd.
12.47
-8.03
-39.17%
HK:6628
Transcenta Holding Limited
0.85
-3.97
-82.37%
HK:6855
Ascentage Pharma Group International
32.62
-44.93
-57.94%
Sirnaomics Ltd. Corporate Events
Sirnaomics Sues Former Management Over US$20 Million Investment
Aug 14, 2026
Sirnaomics Ltd. has filed a Writ of Summons in the High Court of Hong Kong against former members of its management team, including Dr. Lu Yang, Dr. Xiaochang Dai and Mr. Yip Wing Kei, in relation to the group’s approximately US$20 million i...
Sirnaomics Sets Late‑August Board Meeting to Approve Interim 2026 Results
Aug 14, 2026
Sirnaomics Ltd. has scheduled a board meeting for August 28, 2026, to review and approve the interim results for the six months ended June 30, 2026, and to authorize their publication. The announcement signals an upcoming update on the companyR...
Sirnaomics Completes HK$11.3 Million Share Subscription Under General Mandate
Aug 12, 2026
Sirnaomics Ltd. has completed a share subscription under its general mandate, issuing 2,435,600 new shares at HK$4.69 each to a single subscriber, raising net proceeds of approximately HK$11.3 million. The funds will be used as general working cap...
Sirnaomics Hits Phase II Milestone for RNA-Based Aesthetic Fat-Reduction Therapy
Jul 30, 2026
Sirnaomics Ltd. has reported the completion of first-patient dosing in its Phase II multi-center clinical trial of STP705 for medical aesthetic use, marking a notable clinical milestone for its RNA-based aesthetic pipeline. The study aims to evalu...
Sirnaomics Forms High-Profile Scientific Advisory Board to Bolster RNA Therapeutics Pipeline
Jul 21, 2026
Sirnaomics Ltd. has formed an external Scientific Advisory Board to guide research and development across its therapeutic pipeline, underscoring its intention to strengthen scientific rigor and regulatory readiness in RNA drug development. The boa...
Sirnaomics Wins Strong Shareholder Backing for New 2026 Equity Incentive Schemes
Jun 30, 2026
Sirnaomics Ltd. reported that shareholders at its extraordinary general meeting on June 30, 2026 approved new 2026 restricted share unit and share option schemes while terminating the corresponding 2022 plans. The resolutions, including a new sche...
Sirnaomics Chairman Raises Stake, Signaling Confidence in Growth Prospects
Jun 24, 2026
Sirnaomics Ltd. announced that its chairman and executive director, Dr. Poon Hung Fai, has increased his stake in the company by purchasing 20,300 shares on the open market at an average price of about HK$5.00 per share, using personal funds. Foll...
Sirnaomics Wins Strong Shareholder Backing for AGM Resolutions and Capital Mandates
Jun 23, 2026
Sirnaomics Ltd. reported that all resolutions at its June 23, 2026 annual general meeting were approved by shareholders via poll, including the adoption of the 2025 audited financial statements and the re-election of several non-executive and inde...
Sirnaomics Sets EGM to Revamp Equity Incentive Schemes
Jun 9, 2026
Sirnaomics Ltd., a Hong Kong-listed biotechnology company specializing in RNA-based therapeutics, develops innovative gene-silencing drugs aimed at global biopharmaceutical markets. Its governance structure includes an executive chairman, a non-ex...
Sirnaomics Reshapes Board Committees After Non-Executive Director Resigns
Jun 5, 2026
Sirnaomics Ltd. announced the resignation of non-executive director Ouyang Yunlong, who also stepped down from the audit and remuneration committees, effective June 5, 2026, citing a need to focus on other commitments. The company noted there was ...
Sirnaomics Sets Out Board and Committee Structure
Jun 5, 2026
Sirnaomics Ltd. has announced the current composition of its board of directors, led by Executive Director Dr. Poon Hung Fai, who serves as both chairman and chief executive officer. The board also includes one non-executive director and three ind...
Sirnaomics Clarifies Discounted Share Subscription Terms and Conditionality
Jun 1, 2026
Sirnaomics Ltd. has issued a supplemental announcement clarifying details of a planned subscription of new shares under its general mandate, including the benchmarked price of HK$5.77 per share and a subscription price of HK$4.69, representing dis...
Sirnaomics Sets 2026 AGM to Renew Mandates and Re-elect Directors
May 28, 2026
Sirnaomics has called its annual general meeting for June 23, 2026, in Hong Kong, where shareholders will review and adopt the audited financial statements for the year ended December 31, 2025. The agenda includes re-election of five directors, au...
Sirnaomics to Raise Capital via Discounted Share Subscription Under General Mandate
May 25, 2026
Sirnaomics Ltd. has entered into a subscription agreement with an investor to issue 2,435,600 new shares at HK$4.69 each under its existing general mandate, representing about 2.22% of its current share capital and 2.17% on an enlarged basis. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.